Health
Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer’s Disease – PRNewswire
/PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical…
LEXINGTON, Mass., March 24, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial (NCT01409915) evaluating the use of Leukine® (sargramostim, yeast-derived rhuGM-CSF) in patients with mild-to-moderate AD. Participants were evaluated for safety and tolerability, as well as cognitive function and markers of AD pathology. Professor Huntington Potter, together with Jonathan Woodcock, Timothy…
-
Business23 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
General24 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
Noosa News10 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General23 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts